



PATIENT APPLICATION FORM

PATIENT'S DETAILS



NAME:	ABUSAD
MOTHER NAME:	SAHANA BEGUM
DATE OF BIRTH / AGE:	12 Years
SEX:	MALE
ADDRESS:	Vill-Dhanapur, Distt-Chandauli, Uttar Pradesh-232105
DISEASE:	rB-ALL (Acute Lymphoblastic Leukemia Relapse) / Blood Cancer
HOSPITAL DEPARTMENT TREATMENT	BHU, Varanasi (UP) Oncology Allogenic Stem Cell Transplant

For CANCER CARE TRUST

Authorized Signatory

Authorized Sign

Parent's Sign

Patients Name- Abusad
Age/Sex - 11 years/ Male
Specimen - Peripheral Blood Smear, Bone Marrow Aspiration
Referred by: Prof. V Gupta

MRD: 4814598
Ward - Paediatrics III
Report No.-603/26

Follow up case of B cell Acute Lymphoblastic Leukemia with relapse

Peripheral Blood Smear:

- **RBC:** Mild anisocytosis with normocytic normochromic, occasional elongated and tear drop cells and fragmented cells..
- **WBC:** TLC- Within normal range.
DLC- N₆₄ L₂₉ E₀₁ M₀₆. Occasional atypical cells are also appreciated.
- **Platelets:** Adequate.
- No hemoparasites seen.

Bone Marrow Aspiration:

Parameter	Bone marrow aspiration(BMA)
Particle	Particulate.
Cellularity	Normocellular, diluted with blood, taking background stain.
M:E	1.7:1
Erythropoiesis	Predominantly megaloblastic.
Myelopoiesis	Pm ₀₂ My ₁₄ Mm ₁₅ N ₃₂ L ₀₂ Ery ₃₅ with giant metamyelocytes.
Megakaryopoiesis	Seen in fair number.

Opinion- Acute Lymphoblastic leukemia - in hematological remission with megaloblastic erythropoiesis.


Dr Atreyee Chakraborty
Junior Resident

Date of Receipt- 07/02/26
Date of Dispatch- 09/02/26


Prof. Sandip Kumar
Professor
Department of Pathology

Banaras Hindu University, Sir Sunderlal Hospital
(Under PM, CM, Ayushman Bharat Yojana and other Funds)

MRD No. 517764184598

DRUG SLIP

Date 10/2/26

Bed No. 09

Name of Patient

Abusad

Ward/Service B.M.T

Quantity

Sr. No.	Name of Items / Drugs	Quantity
1	inj - Parathyroid (12.5/5)	2
2	Tab - Lan 20 (30)	10
3	Tab - endem (4mg)	10
4	inj - Appripitan	10
5	Syp - Zincovit	10
6	Syp - Vitid combi	10
7	Syp - Curical - P (200/5)	10
8	Syp - mucain gel	10
9	Syp - Pakt 101	10
10	Tab - Leura (500)	10
11	Syp - Lafstop	10

Full Signature of Nursing Staff with EID

रवा प्राप्तकर्ता के हस्ताक्षर

Banaras Hindu University, Sir Sunderlal Hospital
(Under PM, CM, Ayushman Bharat Yojana and other Funds)

MRD No. 517754184598

DRUG SLIP

Date 10/02/26

Bed No. 09

Name of Patient

Abusad

Ward/Service B.M.T

Quantity

Sr. No.	Name of Items / Drugs	Quantity
1	inj - Busulphan (60/10)	2
2	inj - methylphen (50mg)	10
3	inj - cyclophosphamide (200mg)	10
4	inj - cyclophosphamide (1000mg)	10
5	inj - Cyclosporin (Soln)	10
6	Cap - Cyclosporin (100)	10
7	inj - Musna (200mg)	10
8	Tab - levoflox (250mg)	10
9	Tab - ACIVIR (400)	10
10	Tab - Valiconazol (200)	10
11	Tab - Metrogyl (400)	10

Full Signature of Nursing Staff with EID

रवा प्राप्तकर्ता के हस्ताक्षर

Banaras Hindu University, Sir Sunderlal Hospital
(Under PM, CM, Ayushman Bharat Yojana and other Funds)

MRD No. 517774184598

DRUG SLIP

Date 10/2/26

Bed No. 09

Name of Patient

Abusad

Ward/Service B.M.T

Quantity


Sr. No.	Name of Items / Drugs	Quantity
1	Tab - shulcal 500	10
2	Zytee RB gel	10
3	Metrogyl per gel	10
4	Thrombophob ointment	10
5	Anfun moult paint	10
6	Vit - D sachet (D-Blast) (60000)	4

Full Signature of Nursing Staff with EID

रवा प्राप्तकर्ता के हस्ताक्षर



MC-2024



Lab Facility: Unipath House, Beside Sahjanand college, Opposite Kamdeni Complex, Panjrapole, Ambawadi, Ahmedabad-380015
Unigenome: 2A, 3A, 3B PMSL - House, Beside Sahjanand college, Opposite Kamdeni Complex, Panjrapole, Ambawadi, Ahmedabad-380015, Gujarat
Phone: +91-79-49006800, 07659991171 | Whatsapp: 6356005900 | Email: info@unipath.in | Website: www.unipath.in

LABORATORY REPORT



Reg. No	: 60241200068	Reg. Date	: 07-Feb-2026 17:24
Name	: ABBUSHAD	Collection on	: 06-Feb-2026 17:24
Sex/Age	: Male / 12 Years	Report Date	: 09-Feb-2026 13:22
Ref. By	: Dr. PROF.VINEETA GUPTA (PRD.ONCO&HEMATLOGY)	Tele. No	:
Location	: UNIPATH COCO @ VARANASI	Dispatch At	:

IMMUNOPHENOTYPING REPORT
Minimal residual disease (MRD) for B ALL

Clinical diagnosis: K/C/O B ALL, Previous MRD was negative done on date 17/10/2025

Treatment protocol:

MRD testing time point: -

Sample type: Bone marrow EDTA

Method / Instrument / Software: Flowcytometry / Beckman Coulter DxFLEX/ Kaluza 2.3

Gating strategy: 11 color FCM using CD45 gating

Cell preparation Method: Bulk lyse - stain - wash

Panel: CD304 / CD73 / CD20 / CD123 / CD19 / CD34 / CD10 / CD24 / CD38 / CD22 / CD45

Viability: 96.18%,

Hemodilution assessment: CD19 cells: 0.00%, Myeloblasts: 2.61%, Plasma cells: 0.02%

Acquired events: ~ 25.00 L

Analysed viable events: ~20.98 L (based on FSC vs SSC plot and singlet)

MRD events: 106

MRD: 0.01%

Result:

Marker	Expression	Interpretation	Marker	Expression	Interpretation
CD45	Moderate	Positive	CD34	Variable	Positive
CD19	Bright	Positive	CD73	-	Negative
CD20	Moderate	Positive	CD304	-	Negative
CD38	Moderate	Positive	CD123	Moderate	Positive
CD10	Bright	Positive	CD24	Bright	Positive
CD22	Bright	Positive (100%)			

Aberrancy detected: underexpression of CD73 and overexpression of CD10, CD24, CD20


Galande

Dr. Mohan Galande
M.D. Pathology
G-10116

This is an electronically authenticated report. *Please verify the authenticity of this report by scanning the QR code to ensure data integrity.*



LABORATORY REPORT



Reg. No	: 60241200068	Reg. Date	: 07-Feb-2026 17:24
Name	: ABBUSHAD	Collection on	: 06-Feb-2026 17:24
Sex/Age	: Male / 12 Years	Report Date	: 09-Feb-2026 13:22
Ref. By	: Dr. PROF.VINEETA GUPTA (PRD.ONCO&HEMATLOGY)	Tele. No	:
Location	: UNIPATH COCO @ VARANASI	Dispatch At	:

Interpretation: Immunophenotypic analysis revealed measurable residual disease 0.01%

Limit of quantification (LOQ): 0.0025% (based on analysed viable events)
Lower Limit of detection (LLOD): 0.0010% (based on analysed viable events)

Note: MRD results are to be correlated with the clinical details, diagnostic immunophenotype and cytogenetic profile of the patient. MRD can be used as an independent prognostic factor for the patient however its role for therapeutic decisions is to be based on the treatment protocol being used for the patient.

It is mandatory to send properly labelled first pull aspirate of upto 1ml for MRD analysis. Additional samples should be sent if low cellularity is expected.

----- End Of Report -----

Cancer Care Trust

Mohand Galande

Dr. Mohan Galande
M.D. Pathology
G-10116



HOMI BHABHA CANCER HOSPITAL, VARANASI
 (A UNIT OF TATA MEMORIAL CENTRE, MUMBAI)
 LAHARTARA, OLD LOCO COLONY, SHIVPURWA, VARANASI, UTTAR PRADESH-221002.



Case No. **16E2025/000063** Requisition No. **UZZ/BF/25/000785** Req. Dt **27/12/2025** Lab. No. **F25000682**
 Name **ABUSAD ...** Category/Status **C/ Out Patient** IP NO. : **VIP25002861**
 Gender / Age **M / 11 Years**
 DMG : **DMG - PAED HEM-LYMPH**

Nature of Material : **,CSF**

29/12/2025

Final Report

Cell Count **Acellular**
 Imprint **Cytospin smears are virtually acellular.**

Immunophenotyping analysis results are as follows :

CD 45	Dim-Neg	CD 10	Moderate	CD 19	Moderate
CD 20	Negative	CD 34	Mod-Dim	CD 38	Moderate
CD 123	Dim-Neg	CD86	Negative	CD73	Moderate
CD 304	Negative				

DNA Index : **DNA Ploidy :**

REMARKS :

Kindly note that the above positive percentage were determined on 19.9% of the gated events on side scatter/CD 45 plots.

Flow Cytometry Analysis Done By : **Mr.Dharmendra Mishra**

Software : **Kaluza(BC)** Method : **Bulk Lyse-Stain-Wash**
 Instruction: **BC DxFlex**

IMPRESSION: **Independent CSF immunophenotypic analysis reveals 12.5% B Lymphoblasts in a known case of B cell Precursor Lymphoblastic Leukemia. More than 4600 singlet events could be analysed.**

NOTE: The assay uses IVD & RUO antibodies

END OF REPORT

Req Dt/Tm: 27-12-2025 /12:55:07PM
 Coll.Dt.Tm: 27-12-2025 /01:15:32PM
 Recd.Dt/Tm: 27-12-2025 /01:15:38PM
 Commit Dt.Tm: 29-12-2025 /02:57:42PM

ENTERED BY:
 MR. VIKAS SINGH
 Dr. DEEPALI SAXENA
 FELLOW I

COMMITTED BY:
 Dr. NEHA SINGH
 Professor F & Incharge Hematopathology

Final Report



Acute Lymphoblastic Leukemia

Name: <u>Abu Shaad</u>	Age: <u>12 yrs</u>	Sex: <u>M</u>	Wt: <u>34 kg</u>	BSA:	POC NO.
------------------------	--------------------	---------------	------------------	------	---------

RISK STRATIFICATION

Date	CSF (r/m)				CSF Blast	CSF Flowcytometry
	TC	DC	Glucose	Protein		
<u>27/10/25</u>						<u>Acellular 2-12.5% B-lymphoblast</u>

Factors	Standard risk	Intermediate risk	High risk(anyone)
Age	1-10 yrs	Criteria not meeting either standard risk or high risk	>10 yrs & < 1yr
Total counts	<50,000		≥50,000
Type	B-cell		T-cell, pro b-cell
CNS status	1		2 & 3
Translocations			MLI rearrangement, t(9:22), t(17:19), iamp 21
DNA ploidy	Hyperdiploidy (DNA index >1.16)		t(1:19) Hypodiploidy (DNA index <0.81)

TREATMENT PROTOCOL

Standard risk	Intermediate risk	High risk
1. Induction (without Daunorubicin)	1. Induction (with 2 doses of Daunorubicin)	1. Induction (with 4 doses of Daunorubicin)
2. Interim maintenance	2. BFM Consolidation	2. BFM Consolidation
3. Capizzi	3. Capizzi	3. Capizzi
4. Delayed intensification I & II	4. Delayed intensification I & II	4. Intermediate dose methotrexate
5. Maintenance	5. Maintenance	5. Delayed intensification I & II
		6. Maintenance

RE EVALUATION

	DATE	MRD	BMA
POST INDUCTION			